Pfizer (PFE) said Friday that its pivotal phase 3 trial evaluating sasanlimab in combination with Bacillus Calmette-Guerin, or BCG, as treatment for non-muscle invasive bladder cancer achieved its primary endpoint of event-free survival.
The study showed that the combination therapy provided a "clinically meaningful and statistically significant improvement" compared with BCG alone, according to Pfizer.
Prolonged event-free survival provided by the investigational treatment may delay or reduce the need for more aggressive treatment options, said Neal Shore, lead investigator for the trial.
The safety profile of sasanlimab in combination with BCG "was generally consistent" with the known profiles of BCG and PD-1 inhibitors, Pfizer added.
The company said sasanlimab is also being investigated in combination with its antibody drug conjugate portfolio in advanced solid tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。